Skip to main content

Table 3 Effectiveness of vaccination against any lung injury, according to age group, sex and study period

From: Gam-COVID-Vac, EpiVacCorona, and CoviVac effectiveness against lung injury during Delta and Omicron variant surges in St. Petersburg, Russia: a test-negative case–control study

  

One-dose Gam-COVID-Vac (Sputnik Light)

Two-dose Gam-COVID-Vac (Sputnik V)

Three-dose Gam-COVID-Vac (booster)

EpiVacCorona

CoviVac

Age (categories)

18–30

81% (50 to 92)

67% (58 to 73)

74% (60 to 83)

-60% (− 309 to 37)

28% (− 13 to 55)

 

31–40

69% (48 to 82)

67% (61 to 71)

68% (58 to 76)

− 8% (− 97 to 41)

63% (48 to 74)

 

41–50

70% (53 to 81)

56% (49 to 61)

65% (56 to 72)

− 36% (− 137 to 22)

34% (12 to 51)

 

51–60

76% (64 to 84)

55% (48 to 61)

69% (61 to 75)

0% (− 72 to 42)

44% (25 to 57)

 

61 +

78% (68 to 84)

50% (43 to 55)

74% (70 to 78)

33% (0 to 55)

57% (40 to 69)

Sex

Female

70% (62 to 77)

56% (53 to 60)

71% (67 to 75)

− 11% (− 53 to 20)

49% (39 to 57)

 

Male

81% (72 to 87)

57% (52 to 61)

71% (65 to 76)

20% (− 20 to 47)

37% (19 to 52)

Period

Delta

57% (32 to 72)

59% (55 to 62)

57% (48 to 64)

− 35% (− 100 to 9)

41% (27 to 52)

 

Omicron

54% (40 to 64)

38% (32 to 44)

57% (51 to 63)

5% (− 43 to 37)

30% (12 to 44)